These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
330 related articles for article (PubMed ID: 18082281)
1. The oral absorption of phospholipid prodrugs: in vivo and in vitro mechanistic investigation of trafficking of a lecithin-valproic acid conjugate following oral administration. Dahan A; Duvdevani R; Shapiro I; Elmann A; Finkelstein E; Hoffman A J Control Release; 2008 Feb; 126(1):1-9. PubMed ID: 18082281 [TBL] [Abstract][Full Text] [Related]
2. A novel mechanism for oral controlled release of drugs by continuous degradation of a phospholipid prodrug along the intestine: in-vivo and in-vitro evaluation of an indomethacin-lecithin conjugate. Dahan A; Duvdevani R; Dvir E; Elmann A; Hoffman A J Control Release; 2007 May; 119(1):86-93. PubMed ID: 17382425 [TBL] [Abstract][Full Text] [Related]
3. The effect of different lipid based formulations on the oral absorption of lipophilic drugs: the ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats. Dahan A; Hoffman A Eur J Pharm Biopharm; 2007 Aug; 67(1):96-105. PubMed ID: 17329087 [TBL] [Abstract][Full Text] [Related]
4. Lymphatic transport of Methylnortestosterone undecanoate (MU) and the bioavailability of methylnortestosterone are highly sensitive to the mass of coadministered lipid after oral administration of MU. White KL; Nguyen G; Charman WN; Edwards GA; Faassen WA; Porter CJ J Pharmacol Exp Ther; 2009 Nov; 331(2):700-9. PubMed ID: 19696095 [TBL] [Abstract][Full Text] [Related]
5. Targeted delivery of a model immunomodulator to the lymphatic system: comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies. Han S; Quach T; Hu L; Wahab A; Charman WN; Stella VJ; Trevaskis NL; Simpson JS; Porter CJ J Control Release; 2014 Mar; 177():1-10. PubMed ID: 24398334 [TBL] [Abstract][Full Text] [Related]
6. Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States. Dutta S; Reed RC Epilepsy Res; 2007 Mar; 73(3):275-83. PubMed ID: 17208410 [TBL] [Abstract][Full Text] [Related]
7. Disposition of beta-glucuronidase-resistant "glucuronides" of valproic acid after intrabiliary administration in the rat: intact absorption, fecal excretion and intestinal hydrolysis. Dickinson RG; Kluck RM; Eadie MJ; Hooper WD J Pharmacol Exp Ther; 1985 Apr; 233(1):214-21. PubMed ID: 3920383 [TBL] [Abstract][Full Text] [Related]
8. Bioavailability of seocalcitol II: development and characterisation of self-microemulsifying drug delivery systems (SMEDDS) for oral administration containing medium and long chain triglycerides. Grove M; Müllertz A; Nielsen JL; Pedersen GP Eur J Pharm Sci; 2006 Jun; 28(3):233-42. PubMed ID: 16650738 [TBL] [Abstract][Full Text] [Related]
9. Lipid-based formulations to enhance oral bioavailability of the poorly water-soluble drug anethol trithione: effects of lipid composition and formulation. Han SF; Yao TT; Zhang XX; Gan L; Zhu C; Yu HZ; Gan Y Int J Pharm; 2009 Sep; 379(1):18-24. PubMed ID: 19508887 [TBL] [Abstract][Full Text] [Related]
10. Bioavailability of seocalcitol III. Administration of lipid-based formulations to minipigs in the fasted and fed state. Grove M; Müllertz A; Pedersen GP; Nielsen JL Eur J Pharm Sci; 2007 May; 31(1):8-15. PubMed ID: 17383165 [TBL] [Abstract][Full Text] [Related]
11. Investigation of low levels of plasma valproic acid concentration following simultaneous administration of sodium valproate and rizatriptan benzoate. Hokama N; Hobara N; Kameya H; Ohshiro S; Hobara N; Sakanashi M J Pharm Pharmacol; 2007 Mar; 59(3):383-6. PubMed ID: 17331341 [TBL] [Abstract][Full Text] [Related]
12. Examination of lymphatic transport of puerarin in unconscious lymph duct-cannulated rats after administration in microemulsion drug delivery systems. Wu H; Zhou A; Lu C; Wang L Eur J Pharm Sci; 2011 Mar; 42(4):348-53. PubMed ID: 21216284 [TBL] [Abstract][Full Text] [Related]
14. Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: Performance and mechanism. Gao F; Zhang Z; Bu H; Huang Y; Gao Z; Shen J; Zhao C; Li Y J Control Release; 2011 Jan; 149(2):168-74. PubMed ID: 20951749 [TBL] [Abstract][Full Text] [Related]
15. The disposition of valpromide in rats and the isolated perfused rat liver. Billig H; Ziv E; Bar-On H; Bialer M Drug Metab Dispos; 1990; 18(2):238-44. PubMed ID: 1971580 [TBL] [Abstract][Full Text] [Related]
16. Time course of alpha-fluorinated valproic acid in mouse brain and serum and its effect on synaptosomal gamma-aminobutyric acid levels in comparison to valproic acid. Tang W; Palaty J; Abbott FS J Pharmacol Exp Ther; 1997 Sep; 282(3):1163-72. PubMed ID: 9316822 [TBL] [Abstract][Full Text] [Related]
17. Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Paliwal R; Rai S; Vaidya B; Khatri K; Goyal AK; Mishra N; Mehta A; Vyas SP Nanomedicine; 2009 Jun; 5(2):184-91. PubMed ID: 19095502 [TBL] [Abstract][Full Text] [Related]
18. Impaired biliary elimination of beta-glucuronidase-resistant "glucuronides" of valproic acid after intravenous administration in the rat. Evidence for oxidative metabolism of the resistant isomers. Dickinson RG; Kluck RM; Wood BT; Eadie MJ; Hooper WD Drug Metab Dispos; 1986; 14(2):255-62. PubMed ID: 2870903 [TBL] [Abstract][Full Text] [Related]
19. Disposition and protein binding of valproic acid in the developing rat. Haberer LJ; Pollack GM Drug Metab Dispos; 1994; 22(1):113-9. PubMed ID: 8149869 [TBL] [Abstract][Full Text] [Related]
20. In vitro evaluation of dendrimer prodrugs for oral drug delivery. Najlah M; Freeman S; Attwood D; D'Emanuele A Int J Pharm; 2007 May; 336(1):183-90. PubMed ID: 17188439 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]